Background
Myxoid liposarcoma (MLS) is a rare type of soft tissue sarcoma, most often arising in the trunk or extremities. Unlike many other sarcomas, MLS is known to be relatively sensitive to radiotherapy. That characteristic has led researchers to ask an important question: can the usual preoperative radiation dose be safely reduced without sacrificing tumor control?
For most soft tissue sarcomas, standard preoperative radiotherapy is typically delivered to a total dose of 50 Gy. In MLS, however, earlier prospective studies suggested that lower doses might still achieve excellent local control while potentially reducing treatment-related harm, especially wound complications after surgery. The DOREMY trial was designed to test that idea. This long-term follow-up report provides a more complete picture of both benefit and safety.
